Form 4: Beam Therapeutics Executive Sells Shares for Tax Withholding
Statement of Changes in Beneficial Ownership
Beam Therapeutics Chief Medical Officer Amy Simon sold 373 shares of common stock on June 30, 2026, to cover tax withholding obligations upon the vesting of restricted stock units.
Summary
- Amy Simon, Chief Medical Officer at Beam Therapeutics Inc., sold 373 shares of common stock on June 30, 2026.
- The sale was executed at a price of $34.73 per share.
- These shares were sold automatically to cover tax withholding obligations related to the vesting of restricted stock units.
- The transaction was part of a Rule 10b5-1 trading plan adopted by Ms. Simon on May 19, 2023.
- Following the transaction, Ms. Simon beneficially owns 102,363 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the stock sale is a routine, non-discretionary transaction for tax purposes under a pre-established trading plan.
Negatives
- Sale of company stock by a key executive, although for tax purposes, can sometimes be perceived negatively by the market.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The sale by Chief Medical Officer Amy Simon is attributed to tax withholding upon vesting of RSUs, a common occurrence and typically executed under pre-arranged trading plans like Rule 10b5-1 to avoid insider trading concerns.
Stakeholder Impact
- Shareholders: The sale is for tax withholding and executed under a 10b5-1 plan, suggesting no immediate negative impact on shareholder value due to insider selling pressure. However, any insider selling can be a point of observation for investors.
- Employees: The transaction relates to employee equity compensation (RSUs) and tax obligations, a standard aspect of executive compensation.
- Management: The transaction reflects standard executive compensation practices and compliance with SEC regulations.
Key Dates
| Date | Description |
|---|---|
| 05/19/2023 | Date Rule 10b5-1 trading plan was adopted by Amy Simon. |
| 06/30/2022 | Date restricted stock units were granted to Amy Simon (implied by explanation). |
| 06/30/2026 | Date of the stock sale transaction. |
| 07/02/2026 | Date the Form 4 was signed by the attorney-in-fact. |
Keywords
Form 4, SEC Filing, Beam Therapeutics, BEAM, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, Rule 10b5-1, Amy Simon, Chief Medical Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.